Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Cell Signaling Technology, Inc. Expands its PhosphoScan Patent Portfolio
April 11th, 2007
Cell Signaling Technology, Inc. (CST) announced that it has obtained a notice of allowance from the U.S. Patent & Trademark Office allowing its patent entitled "Immunoaffinity Isolation of Modified Peptides from Complex Mixtures" (Rush et al., U.S. Pat. No. 7,198,896). The patented technology, which CST commercializes under the trademarks PhosphoScan(R) and AcetylScan(R), covers the selective isolation of a target population of post-translationally modified peptides from a complex mixture of peptides by using immobilized modification-specific antibodies, followed by mass spectrometric determination of modification sites and parent protein identification. The technology is uniquely...
Source: Medical Patent Law Weekly (2007-04-11)
|
|
Advertisement |
|
|
|
